Navigation Links
Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
Date:6/16/2008

l long-term treatment

program for these patients.

About InterCure Ltd. and RESPeRATE

InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) (http://www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug therapy with no side effects.

RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device's efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.

With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world's most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.

InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
'/>"/>

SOURCE InterCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
4. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
5. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
6. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
7. Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
8. New Study Linking High Normal Blood Pressure to Significant Cardiovascular Risk
9. Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
10. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS ... New York results of AFF008, a Phase I ... is the first therapy against the protein alpha-synuclein, a promising ... Michael J. Fox Foundation for Parkinson,s Research (MJFF) supported the ... the press conference on the impact a disease-modifying therapy would ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... , July 31, 2014 Vermillion, Inc. (NASDAQ: ... women,s health, will hold a conference call on Thursday, August ... for the second quarter ended June 30, 2014. Financial results ... call. Vermillion,s Chairman, President and CEO James ... and answer period. Date: Thursday, August 14, 2014 ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... 02, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... develops,and commercializes differentiated products for patients ... randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) ... following orthopedic surgery.,AeroLEF(TM) met the primary ...
... 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) ... clinical trial,of Fampridine-SR in people with multiple ... meeting. Andrew Goodman, M.D.,Director of the Multiple ... top-line results on walking ability, leg,strength, spasticity ...
Cached Medicine Technology:YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. ... Court has made the determination that a purchaser of tangible ... taxpayer was unable to prove during an audit that ... the Court of Appeals decision on whether a purchaser bears ... for purchases from Michigan sellers. The Court states “in order ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... recently released their innovative compression elbow sleeve , ... other elbow pain, in two new bright colors for ... neon pink and blue. Made of innovative proprietary Zensah® ... moisture wicking and odor-preventing fabric. It features a no-slip ...
(Date:7/31/2014)... 2014 Parker Waichman, LLP, a national ... comments that whistleblowers are a critical component of the ... that may cause harm to consumers and may defraud ... Appreciation Day. , According to a 2013 report issued ... declared "National Whistleblower Appreciation Day" on July 30, 2013; ...
(Date:7/31/2014)... 31, 2014 CarePoint Health is ... Masood Rizvi, has joined our network, CarePoint Health ... the community. Hundreds of highly skilled and experienced ... network of top doctors and practices in Hudson ... latest acquisition represents CarePoint Health’s commitment to provide ...
(Date:7/31/2014)... CT (PRWEB) July 31, 2014 You’re having ... So why have you suddenly developed chills and fever, headache, ... If you suspect a flu-like illness, it could actually be ... , Your risk of developing Lyme is greater than you ... 30,000 new cases occurred in the U.S. annually. But the ...
Breaking Medicine News(10 mins):Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 2Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 4Health News:Dr. Rizvi Joins CarePoint Health Medical Group 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3
... equal for both procedures , , FRIDAY, May 16 ... for colon cancer produce similar outcomes, according to researchers ... 3,300 patients. , "For a long time, many ... in colorectal cancer patients and cause metastases in the ...
... ,Click It or Ticket ... Local high schoolers display art and videos promoting seat belt use, CLEVELAND, May ... mobilization, When: Monday, May 19, 2008 ... 11:30 AM), Where: The Cleveland House of Blues ...
... of CSL Behring, maker of Zemaira(R), Alpha-1 Proteinase Inhibitor (Human) ... ... PRUSSIA, Pa., May 17 Melissa Biggs, a fashion,designer and actress who ... of CSL Behring, and is,urging Americans to get tested for alpha-1 antitrypsin ...
... & Back; Merger Sets Up Healthy ... Back Retail Chain, LORTON, Va., May 16 ... and workplace back wellness created an,ergonomic revolution, has acquired ... Healthy Back,s 18 stores and ecommerce division,claimed 2007 revenues ...
... There,s more to a healthy mouth than,flashing a ... America,s oral care,habits - and what it means ... report from Oral Health America & Philips Sonicare ... video, audio, text, graphics and,photos for free and ...
... report side effects, but critics want agency to act, ... -- Direct-to-consumer drug ads on television should include a ... adverse side effects, U.S. health experts suggested Friday. , ... U.S. Food and Drug Administration. Such phone numbers are ...
Cached Medicine News:Health News:Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:The Back Wars Come to a Close 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3
Gills Colibri forceps, very fine pointed tips....
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Girard angled tying forceps made of titanium has angled 45 shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 102 mm....
McPherson curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 85 mm....
Medicine Products: